[{"id":"945e65a9-39d0-4f4e-af4c-2cf12651eec9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03853616","created_at":"2021-01-18T19:01:11.778Z","updated_at":"2024-07-02T16:35:28.132Z","phase":"Phase 1/2","brief_title":"MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)","source_id_and_acronym":"NCT03853616","lead_sponsor":"Miltenyi Biomedicine GmbH","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zorpocabtagene autoleucel (MB-CART 19.1)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/26/2018","start_date":" 11/26/2018","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-24"},{"id":"b646a546-d119-4f84-848d-1c91125e0b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT03467256","created_at":"2021-01-18T17:05:17.525Z","updated_at":"2024-07-02T16:35:54.760Z","phase":"Phase 1/2","brief_title":"CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL","source_id_and_acronym":"NCT03467256","lead_sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • fludarabine IV • Actemra IV (tocilizumab) • zorpocabtagene autoleucel (MB-CART 19.1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 10/15/2020","primary_completion_date":" 10/15/2020","study_txt":" Completion: 10/15/2025","study_completion_date":" 10/15/2025","last_update_posted":"2023-02-24"},{"id":"ab60cb96-ea59-4502-a17b-321f0a2c6cbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03321123","created_at":"2021-01-18T16:24:01.898Z","updated_at":"2024-07-02T16:37:16.902Z","phase":"Phase 2","brief_title":"MB-CART19.1 in Patients With R/R ALL","source_id_and_acronym":"NCT03321123","lead_sponsor":"Shanghai Children's Medical Center","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • zorpocabtagene autoleucel (MB-CART 19.1)"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2017-10-25"}]